-
'Personality' the key for Celtic boss Nancy when it comes to new signings
-
Arteta eager to avoid repeat of Rice red card against Brighton
-
Nigeria signals more strikes likely in 'joint' US operations
-
Malaysia's former PM Najib convicted in 1MDB graft trial
-
Elusive wild cat feared extinct rediscovered in Thailand
-
Japan govt approves record budget, including for defence
-
Seoul to ease access to North Korean newspaper
-
History-maker Tongue wants more of the same from England attack
-
Australia lead England by 46 after 20 wickets fall on crazy day at MCG
-
Asia markets edge up as precious metals surge
-
Twenty wickets fall on day one as Australia gain edge in 4th Ashes Test
-
'No winner': Kosovo snap poll unlikely to end damaging deadlock
-
Culture being strangled by Kosovo's political crisis
-
Main contenders in Kosovo's snap election
-
Australia all out for 152 as England take charge of 4th Ashes Test
-
Boys recount 'torment' at hands of armed rebels in DR Congo
-
Inside Chernobyl, Ukraine scrambles to repair radiation shield
-
Bondi victims honoured as Sydney-Hobart race sets sail
-
North Korea's Kim orders factories to make more missiles in 2026
-
Palladino's Atalanta on the up as Serie A leaders Inter visit
-
Hooked on the claw: how crane games conquered Japan's arcades
-
Shanghai's elderly waltz back to the past at lunchtime dance halls
-
Japan govt approves record 122 trillion yen budget
-
US launches Christmas Day strikes on IS targets in Nigeria
-
Australia reeling on 72-4 at lunch as England strike in 4th Ashes Test
-
Too hot to handle? Searing heat looming over 2026 World Cup
-
Packers clinch NFL playoff spot as Lions lose to Vikings
-
Guinea's presidential candidates hold final rallies before Sunday's vote
-
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
-
Loar Holdings Inc. Announced The Completion of its Acquisition of LMB Fans & Motors
-
IRS Can Freeze Installment Agreements After Missed Filings - Clear Start Tax Explains Why Compliance Comes First
-
How the Terms of SMX's $111 Million Capital Facility Shape the Valuation Discussion
-
A Christmas Message to the DEA's Diversion Anti Marijuana Cabal
-
QAT Community Sets QuantumTrade 5.0 for Public Beta Testing in March 2026
-
BondwithPet Expands B2B Offering with Custom Pet Memorial Product
-
Best Crypto IRA Companies (Rankings Released)
-
Eon Prime Intelligent Alliance Office Unveils New Brand Identity and Completes Website Upgrade
-
Villa face Chelsea test as Premier League title race heats up
-
Spurs extend domination of NBA-best Thunder
-
Malaysia's Najib to face verdict in mega 1MDB graft trial
-
King Charles calls for 'reconciliation' in Christmas speech
-
Brazil's jailed ex-president Bolsonaro undergoes 'successful' surgery
-
UK tech campaigner sues Trump administration over US sanctions
-
New Anglican leader says immigration debate dividing UK
-
Russia says made 'proposal' to France over jailed researcher
-
Bangladesh PM hopeful Rahman returns from exile ahead of polls
-
Police suspect suicide bomber behind Nigeria's deadly mosque blast
-
AFCON organisers allowing fans in for free to fill empty stands: source
-
Mali coach Saintfiet hits out at European clubs, FIFA over AFCON changes
-
Last Christians gather in ruins of Turkey's quake-hit Antakya
Japan firm probing 76 more deaths in supplement scare
Japanese health supplement maker Kobayashi Pharmaceutical said Friday it was probing 76 more deaths possibly linked to its tablets containing red yeast rice, meant to lower cholesterol.
It deepens a scandal that erupted earlier this year when the company said it was looking into five deaths potentially linked to the over-the-counter products after dozens of customers reported kidney problems.
Fermented with a mould culture, red yeast rice, or "beni koji", has been used in food, alcoholic drinks and folk medicines for centuries around East Asia.
"Even if the direct cause of hospitalisation or death was not kidney-related disease, it has become clear that there are a variety of cases, including cases in which beni koji-related products may have caused harm somehow and had some indirect impact," a Kobayashi statement said.
Of the five initial deaths under investigation, the company said it now knows one did not consume red yeast rice.
"We have received 1,656 inquiries from individuals who have sought medical attention, and have 76 cases under investigation over (a causal) connection to the deaths," in addition to the original four, it said.
On March 22, Kobayashi Pharmaceutical said it was recalling three kinds of tablets containing beni koji.
It later said it had detected a potentially toxic acid produced by the mould at one of its factories, and government officials inspected the firm's facilities.
Kobayashi Pharmaceutical is a household name in Japan, offering a wide range of health-related products, and the scandal has been top news in the country.
On Friday, Kobayashi said it would work to identify the exact cause and scope of the health damage -- including whether organs other than kidneys were harmed.
Top government spokesman Yoshimasa Hayashi said Friday that the health ministry had previously ordered the company to file a daily report on its probe, and demanded more details earlier this month after the number of deaths under investigation didn't change.
"But until today, it had not reported the specific number of cases under investigation, and it is extremely regrettable," Hayashi told reporters.
Kobayashi Pharmaceutical has said it also sold red yeast rice to around 50 other firms in Japan and two in Taiwan.
Taiwanese companies preventively recalled 154 products containing red yeast rice in the wake of the scare, the island's health authorities said earlier this year.
P.Santos--AMWN